Accessibility settings

This paper is in the following e-collection/theme issue:

Teledermatology (119) Surveillance Systems (696)

Published on in Vol 5, No 4 (2022): Oct-Dec

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/40623, first published .
Dermengine AI software analyzes a mole on a patient's skin.

Perspectives and Experiences of Patient-Led Melanoma Surveillance Using Digital Technologies From Clinicians Involved in the MEL-SELF Pilot Randomized Controlled Trial: Qualitative Interview Study

Perspectives and Experiences of Patient-Led Melanoma Surveillance Using Digital Technologies From Clinicians Involved in the MEL-SELF Pilot Randomized Controlled Trial: Qualitative Interview Study

Authors of this article:

Dorothy Drabarek1 Author Orcid Image ;   Emily Habgood2 Author Orcid Image ;   Deonna Ackermann1 Author Orcid Image ;   Jolyn Hersch1 Author Orcid Image ;   Monika Janda3 Author Orcid Image ;   Rachael L Morton4 Author Orcid Image ;   Pascale Guitera5, 6, 7 Author Orcid Image ;   H Peter Soyer8, 9 Author Orcid Image ;   Helena Collgros6, 7 Author Orcid Image ;   Anne E Cust1, 5, 10 Author Orcid Image ;   Robyn PM Saw5, 7, 11 Author Orcid Image ;   Jon Emery2 Author Orcid Image ;   Victoria Mar12 Author Orcid Image ;   Mbathio Dieng4 Author Orcid Image ;   Anthony Azzi13, 14 Author Orcid Image ;   Alister Lilleyman13 Author Orcid Image ;   Katy JL Bell1 Author Orcid Image
Article Authors Cited by (10) Tweetations (9) Metrics

Journals

  1. Drabarek D, Ackermann D, Medcalf E, Bell K. Acceptability of a Hypothetical Reduction in Routinely Scheduled Clinic Visits Among Patients With History of a Localized Melanoma (MEL-SELF): Pilot Randomized Clinical Trial. JMIR Dermatology 2023;6:e45865 View
  2. Ackermann D, Hersch J, Janda M, Bracken K, Turner R, Bell K. Using the Behaviour Change Wheel to identify barriers and targeted strategies to improve adherence in randomised clinical trials: The example of MEL-SELF trial of patient-led surveillance for melanoma. Contemporary Clinical Trials 2024;140:107513 View
  3. Federico S, Cassalia F, Mazza M, Del Fiore P, Ferrera N, Malvehy J, Trilli I, Rivas A, Cazzato G, Ingravallo G, Ardigò M, Piscazzi F. Advancements in Diagnosis of Neoplastic and Inflammatory Skin Diseases: Old and Emerging Approaches. Diagnostics 2025;15(16):2100 View
  4. Nopour R. Effectiveness of telemedicine interventions in the care management of melanoma: a systematic review. Informatics for Health and Social Care 2026;51(2):226 View
  5. Medcalf E, Ackermann D, Williams J, Turner R, Espinoza D, Wu Z, Fann A, Kharel P, Janda M, Cust A, Irwig L, Hersch J, Low D, Low C, Guitera P, Martin L, Soyer H, Azzi A, Lilleyman A, Rosengren H, Mar V, Mcrae M, Glanz A, Collgros H, Emery J, Murchie P, Morton R, Ferguson P, McLean C, Bell K. Characteristics of Participants Screened and Randomized to the Melanoma Self Surveillance Trial. JAMA Dermatology 2026;162(5):457 View
  6. Perez D, Mohseni Y, Hartman R. Artificial Intelligence and Teledermatology in Melanoma Detection: Diagnostic Performance and Implementation Challenges. Current Dermatology Reports 2026;15(1) View
  7. Williams J, Bell K, Morton R, Guitera P, Martin L, McAlister S. The carbon footprint of surgical and nonsurgical skin cancer appointments. Clinical and Experimental Dermatology 2026 View
  8. Swain R, Masic M, Staal J, Dangerman N, Barendse E, Wakkee M, Zwaan L. Effect Of Teledermatologist Supervision in AI Skin Cancer Apps on Patients’ Trust And Adherence Intentions: A Randomised Controlled Trial. (Preprint). JMIR mHealth and uHealth 2026 View
  9. Hörold M, Schutkowski S, Drewitz K, Haferkamp S, Schmitt J, Meier F, Bergmann M, Küster B, Pape M, Apfelbacher C. Survivorship care for melanoma patients: a scoping review. Journal of Cancer Survivorship 2026 View

Books/Policy Documents

  1. Patil P, Saravanan C, T. R. V, Dharani A. Future Innovations in the Convergence of AI and Internet of Things in Medicine. View